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Abstract
Background: The inhibition of pyrimidine biosynthesis by blocking the dihydroorotate dehydrogenase (DHODH)
activity, the prime target of leflunomide (LEF), has been proven to be an effective strategy for rheumatoid arthritis (RA)
treatment. However, a considerable proportion of RA patients are refractory to LEF. Here, we investigated lapachol
(LAP), a natural naphthoquinone, as a potential DHODH inhibitor and addressed its immunosuppressive properties.
Methods: Molecular flexible docking studies and bioactivity assays were performed to determine the ability of LAP to
interact and inhibit DHODH. In vitro studies were conducted to assess the antiproliferative effect of LAP using isolated
lymphocytes. Finally, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) models were employed to
address the anti-arthritic effects of LAP.
Results: We found that LAP is a potent DHODH inhibitor which had a remarkable ability to inhibit both human and
murine lymphocyte proliferation in vitro. Importantly, uridine supplementation abrogated the antiproliferative effect of
LAP, supporting that the pyrimidine metabolic pathway is the target of LAP. In vivo, LAP treatment markedly reduced
CIA and AIA progression as evidenced by the reduction in clinical score, articular tissue damage, and inflammation.
Conclusions: Our findings propose a binding model of interaction and support the ability of LAP to inhibit DHODH,
decreasing lymphocyte proliferation and attenuating the severity of experimental autoimmune arthritis. Therefore, LAP
could be considered as a potential immunosuppressive lead candidate with potential therapeutic implications for RA.
Keywords: Rheumatoid arthritis, Lapachol, Inflammation, Collagen-induced arthritis, Dihydroorotate dehydrogenase,
DMARDs, Pyrimidine metabolism
Background
Rheumatoid arthritis (RA) is an autoimmune disease that
is characterized by chronic articular inflammation with
progressive joint destruction [1]. The current first-line
therapy for RA patients includes the use of conventional
disease-modifying antirheumatic drugs (DMARDs), such
as methotrexate or leflunomide (LEF), in combination
with short-term glucocorticoids. Moreover, the use of bio-
logical agents is employed as an alternative therapy in pa-
tients whose disease failed to respond to conventional
DMARDs [2].
LEF is an isoxazole derivative with a potent
immunosuppressive activity that was approved for the
treatment of RA in 1998 [3]. LEF is a prodrug that is con-
verted in vivo to its primary active metabolite A771726
(also known as teriflunomide). LEF blocks lymphocyte
proliferation and hence the clonal expansion of autoreac-
tive T cells in RA patients by inhibiting dihydroorotate de-
hydrogenase (DHODH), the mitochondrial rate-limiting
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enzyme in the de novo synthesis of pyrimidine ribonucleo-
tides [4, 5]. The use of LEF is normally reserved for RA
patients whose disease failed to respond to first-line
DMARDs, before the introduction of biological DMARDs
[6]. Nevertheless, despite it having demonstrated safety
and efficacy, a substantial proportion of patients (around
30–40%) do not have an appropriate response to LEF [7].
Therefore, it is highly desirable to discover novel DHODH
inhibitors as lead compounds for the development of new
DMARD candidates.
Lapachol (LAP; 2-hydroxy-3-(3methyl-2-butenyl)-1,4-
naphthoquinone) is a nonpolar naturally occurring
naphthoquinone found in some Brazilian medicinal
plants [8]. LAP and others naphthoquinones have been
described as having a range of biological actions, includ-
ing microbicidal, anti-inflammatory and antiproliferative
activities [9–15]. In fact, it was demonstrated that LAP
has potent antitumoral activity which was characterized
by its ability to inhibit DNA and RNA synthesis in neo-
plastic cells [16]. Moreover, it was reported that LAP can
reduce proliferation of the human keratinocytes in vitro,
suggesting that it has potential antipsoriatic effects [17].
Despite the molecular mechanisms associated with these
effects remaining poorly elucidated, it has been described
that LAP and other naphthoquinones derivatives, such as
lawsone and atovaquone, can inhibit DHODH activity [9].
However, the biological relevance of this effect was poorly
characterized. In the present study, we investigated the
potential immunosuppressive properties of LAP.
Methods
Preparation of LAP sodium salt
To a solution of LAP (500 mg, 2.06 mmol) in ethanol
(20 ml) was added NaOH (112 mg, 0.28 mmol) and the
reaction mixture was stirred for 24 h. After consumption
of LAP, the reaction mixture was concentrated under re-
duced pressure and the solid residue was washed with
dichloromethane (4×) and petroleum ether (4×) to afford
a purple solid of 518 mg, 95% yield (1H NMR
(300 MHz, D2Od6) δ7.66 (br s, 1H), 7.64 (br s, 1H), 7.53
(br t, J = 9 Hz, 1H), 7.41 (br t, J = 9Hz, 1H), 5.15 (br t, J
= 9Hz, 1H), (3.06, d, J = 6Hz, 2H), 1.72 (s, 3H), 1.63 (s,
3H); 13C NMR (101 MHz, DMSOd6) δ 187.2, 178.4,
169.6, 136.0, 133.2, 131.3, 129.7, 127.5, 125.76 124.81,
124.4, 117.9, 25.59, 20.8, 14.1; HRMS-ESI m/z cald for:
[M +Na]+ = 265.0835; found = 265.0834).
Molecular modeling and docking procedures
We used nine human DHODH high-resolution crystal
structures in complex with the following inhibitors:
DHO1B0033 (PDB id: 4LS0); DSM338 (PDB id: 4OQV);
O57 (PDB id: 4JS3); a brequinar analogue (PDB id:
4JTU); 221290 (PDB ID: 2WV8); amino-benzoic acid in-
hibitor 715 (PDB id: 3KVL); LEF derivative inhibitor 1
(PDB id: 3F1Q); another brequinar analogue (PDB id:
2B0M); and antiproliferative agent A771726 (PDB id:
1D3H). The crystal structure of hDHODH in complex
with antiproliferative agent A771726 (PDB id: 1D3H)
has been considered for flexible docking with A771726
and LAP, and the calculations were carried out using the
GOLD (Genetic Optimisation for Ligand Docking) 5.2
software [18]. GOLD was comprehensively validated, re-
liably identifying the correct binding mode for a large
range of test set cases, in a vast set of independent stud-
ies, with a rate of success in 70–80% of the PDB
protein-ligand structures thus analyzed, such as reported
in the literature [18, 19].
Here, a parameter set including a population of 100
conformers, 100,000 operations, 95 mutations, and 95
crossovers has been used. The simulations were then per-
formed inside a selected region of the active site (sphere
of 8.5 Å radius centered at x = 49.65, y = 42.13, z = –1.54),
keeping the Leu46 side chain flexible (using a rotamers li-
brary). The number of docking simulations to be per-
formed with each inhibitor was specified under 10 GA
(genetic algorithm) runs, once each docking run can
evolve to different ligand poses (pose = conformation +
orientation). Thus, ten poses of highest score (top-ranked
GOLD solutions) obtained for each compound were se-
lected by using the CHEMPLP score function. In this case,
a Piecewise Linear Potential (fPLP) is used to model the
steric complementarity between protein and ligand, and
for CHEMPLP the distance- and angle-dependent hydro-
gen and metal bonding terms from other fitness function
also implemented in GOLD, so called ChemScore, are
considered. CHEMPLP has been found to give the highest
success rates for docking pose prediction as well as virtual
screening experiments against diverse validation test sets
and it was here chosen as the fitness function. Based on
this CHEMPLP function, GOLD classifies the orientations
of the molecules by a decreasing order of affinity (scores)
with the binding site of the receptor [19].
Previous to the docking calculations and after the re-
moval of the ligand as well as crystallographic waters of
the hDHODH/A771726 complex structure, hydrogen
atoms of the residues side chains were added and oriented
in the active site region. Also, suitable 3D structures of the
inhibitors A771726 and LAP were previously built and op-
timized with molecular mechanics (MMFF force field),
followed by Hartree-Fock/Density Functional methods
(full optimization at B3LYP/6-31G* level of calculation),
using the Spartan’06 software.
Pharmacokinetics study design
For administration to Wistar rats, LAP was dissolved in
DMSO:Tween 80:glucose 5% in a proportion of 15:5:80 (v/
v/v), resulting in a solution of 1 mg/ml (for intravenous
(i.v.) administration) and another of 5 mg/ml (for oral
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administration). LAP was administered to rats as an i.v.
bolus dose at 2 mg/kg (n = 7) and at two oral doses of 10
(n = 8) and 25 mg/kg (n = 6). LAP salt was administered as
i.v. (2 mg/kg, n = 6) and oral doses (30 mg/kg equivalent to
27.5 mg/kg of LAP, n = 8). The i.v. doses were injected into
the lateral tail vein, and oral doses were given by gavage.
The doses were chosen based on previous toxicological and
pharmacodynamic studies [20]. At predetermined time
points (30 min before dosing and at 0.08, 0.25, 0.5, 1, 2, 4,
6, 8, 12, and 24 h) after LAP i.v. administration, blood sam-
ples (200–250 μl) were withdrawn into heparinized tubes
via puncture of the lateral tail vein, opposite to the vein
used for drug dosing. The same procedure was carried out
after oral administration of LAP, with blood sampling at
0.25, 0.5, 1, 1.5, 2, 3, 6, 12, 24, and 30 h. After LAP sodium
salt i.v. and oral dosing, blood samples were harvested up
to 10 and 12 h, respectively. Plasma was obtained by centri-
fugation of blood samples (6800 × g, at 4 °C for 10 min)
and stored at –80 °C until analysis by UPLC-MS/MS.
Pharmacokinetic analysis
LAP and LAP sodium salt pharmacokinetic parameters
after i.v. and oral administration were determined from in-
dividual plasma profiles by a noncompartmental approach
(NCA). The peak plasma concentration (Cmax) and the
time of maximum concentration (Tmax) were obtained by
visual inspection of the data from the plasma concentra-
tion–time curve after oral dosing. Pharmacokinetic pa-
rameters such an elimination rate constant (λ), area under
the curve (AUC0–∞), clearance (CLtot), half-life (t1/2),
volume of distribution (Vdss), mean residence time
(MRT), and bioavailability (Fabs) were determined using
classical equations. The compartmental analyses were per-
formed using SCIENTIST v.2.0.1 software (MicroMath®,
USA). One- and two-compartment models with or with-
out weighting schemes were evaluated. The best model to
fit the data was chosen based on the random distribution
of residuals, the correlation coefficient, and the model se-
lection criterion (MSC) given by the software.
The individual plasma profiles of LAP and LAP so-
dium salt after i.v. administration were best described by
a two-compartmental open model. Plasma profiles after
oral administration with two different doses of LAP and
one dose of LAP sodium salt were best described by the
one-compartmental model.
Plasma analysis by UPLC-MS/MS
LAP concentration in plasma samples was determined by a
validated (FDA, US Food and Drug Administration, 2001)
UPLC-MS/MS method [21]. Analyses were run on an
Acquity UPLC BEH (Waters Acquity™) C18 column (2.1 ×
50 mm, 1.7 μm particle size), with a flow of 300 μl/min at
35 °C. A gradient constituted of water (A) and acetonitrile
(B) acidified with 0.1% acetic acid was used as follows:
0 min (90% A), 1 min (75% A), 7 min (50% A), 8.5 min (0%
A) and 9.5 min (100% A). For the triple quadrupole, MS
parameters were set as follows: capillary voltage (2.20 kV);
extractor (3.0 V) source temperature (150 °C), desolvation
temperature (300 °C), cone gas flow (50 l/h), and desolva-
tion gas flow (700 l/h). For quantification, a multiple reac-
tion monitoring method (MRM) was applied. For LAP, the
transition of m/z 243 > 187 using cone energy of 24 V and
collision energy of 19 V was determined as most appropri-
ate for quantification (Calibration curves between 1 and
20,000 ng/ml of LAP, R > 0.99, low quantification limit of
1 ng/ml, and detection limit of 0.1 ng/ml).
Sample preparation for pharmacokinetics studies
A total of 200 μl cold acetonitrile containing internal
standard (2-methyl-amino-lapachol) at 5 μg/ml and
0.05% trifluoroacetic acid was added to 100 μl of plasma
and vortexed for 20 s. Precipitated protein was removed
by centrifugation (6800 × g at 4 °C for 10 min). A total
of 200 μl of the supernatant was diluted with purified
water 1:1 and filtered by a 0.22-μm membrane before
analysis. To prepare the calibration curves, blank plasma
samples were spiked with LAP and further processed as
indicated. Animal samples with concentrations at the
higher upper limit of the calibration curve were diluted
with blank plasma before processing.
Enzymatic assay
hDHODH activity was assessed using a colorimetric con-
tinuous assay that monitors 2,6-dichloroindophenol (DCIP)
reduction. Change in absorbance at 610 nm was monitored
over a period of 60 s at 25 °C using a microplate reader
(Molecular Devices, SpectraMax 384 Plus, California, USA).
The enzymatic reaction was analyzed in a total volume of
195 μl containing 50 mmol/l Tris, pH 8.15, 150 mmol/l
KCl, 0.1% Triton X-100, 1 mmol/l L-dihydroorotate,
100 μmol/l CoQ0, and 60 μmol/l DCIP. The assay was
started with 5 μl of 0.8 μmol/l stock of enzyme prepared in
50 mmol/l HEPES, pH 7.7, 400 mmol/l NaCl, 10% glycerol,
0.05% Thesit, and 1 mmol/l EDTA in a final concentration
of enzyme at 20 nmol/l. A reference measurement was ob-
tained by preparing the same solution without enzyme.
LAP was analyzed in quadruplicate for each concentra-
tion used. LAP sodium salt was prepared as a 10 mmol/l
stock in DMSO. From this solution, dilutions were pre-
pared in the assay mixture to achieve the range of
100 μmol/l to 0.35 nmol/l. Control enzyme activity in the
absence of inhibitor was taken as 100%. The percentage of
activity versus log of LAP concentration graph was drawn.
The half maximal inhibitory concentration (IC50) values
were calculated using a nonlinear fitting of the concentra-
tion–response data to the equation:
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10 log I½ − log IC50½  þ 1
 
Animals
Collagen-induced arthritis (CIA) and antigen-induced
arthritis (AIA) models were carried out in male DBA1/J
mice (10–12 weeks old) and male C57BL/6 mice (6 weeks
old), respectively. The mice were bred and housed in the
animal facility of the Ribeirão Preto Medical School
(FMRP) at University of São Paulo. For the pharmacoki-
netic studies, male Wistar rats (200–300 g) were pur-
chased from the State Foundation for the Research and
Production in Health (FEPPS, Porto Alegre, Brazil). Ani-
mals received water and food ad libitum. All protocols
were conducted in accordance with ethical guidelines and
approved by the Animal Welfare Committee of FMRP
and the Federal University of Rio Grande do Sul (Proto-
cols: 53/2013 and 20244, respectively).
Isolation of CD4 T cells
Human CD4 T cells were purified from the whole blood
of healthy volunteers. Briefly, peripheral blood mono-
nuclear cells (PBMCs) were isolated by Percoll gradient
(Sigma-Aldrich, St. Louis, MO, USA). CD4 T cells were
isolated from PBMCs using Isolation Kit (Miltenyi Bio-
tec, Bergisch Gladbach, Germany). For murine CD4 T
cells, lymph nodes from naive C57BL/6 male mice were
harvested, and CD4 T cells were purified using Isolation
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) ac-
cording to the manufacturer’s recommendations.
Proliferation assay
A total of 1 × 105 CD4 T cells were labeled with 1 μM
Dye Efluor® 670 (eBioscience, San Diego, CA, USA) for
15 min at 37 °C and cultured in RPMI-1640 10% FBS for
4 days in a 96-well U-bottom plate (Falcon, Franklin
Lakes, New Jersey, USA) with the LAP salt diluted in
RPMI-1640 (10, 30, and 100 μM), LEF diluted in RPMI-
1640 (10, 30, and 100 μM; Arava®, Sanofi, France) and/or
uridine (30, 100, and 300 μM; Sigma-Aldrich, St. Louis,
MO, USA) in the presence of anti-CD3 (3 μg/ml) and
anti-CD28 (1.5 μg/ml). The proliferation of CD4 T cells
was determined by dye dilution in flow cytometry ana-
lysis. The results were expressed as the percentage of
suppression using the following formula: [proliferation
of CD4 T cells only – (proliferation of T CD4 cells with
LEF or LAP)/proliferation of CD4 T cells only] × 100.
Collagen-induced arthritis (CIA)
Male DBA/1 J mice were injected i.d. at the base of the
tail with 200 μg bovine type II collagen (CII; a gift from
Dr. David D. Brand, University of Tennessee Health Sci-
ence Center) emulsified in Freund’s complete adjuvant
(CFA) on day 0. Mice were boosted i.d. with CII (200 μg
emulsified in Freund’s incomplete adjuvant (IFA)) on
day 21. Mice were monitored daily for signs of arthritis.
Scores were assigned based on erythema, swelling, or
ankylosis present in each paw on a scale of 0 to 3, giving
a maximum score of 12 per mouse. After arthritis induc-
tion, mice were treated orally with LAP (3 mg/kg and
10 mg/kg) or LEF (3 mg/kg) or saline daily. The clinical
score was addressed every day after collagen boost. All
mice were euthanized for histologic assessment of the
hind limbs 4 weeks after the boost.
Histological analysis
Femur-tibial joints were collected 4 weeks after CII boost,
fixed in 4% (vol/vol) buffered formalin and decalcified in
10% EDTA for 2–3 weeks. The tissues were then trimmed,
dehydrated in ethanol, and embedded in paraffin for the
preparation of the slides. Histological assessment was car-
ried out following routine staining. Joint sections were
stained with hematoxylin and eosin (H&E) to analyze
synovitis (inflammatory cell influx and synovial hyperpla-
sia) or Safranin-O to visualize proteoglycan depletion and
cartilage destruction. The severity of the joint damage was
scored according to the criteria described by Wang et al.
[22]: 0 = no destruction; 1 =minimal erosion; 2 = slight to
moderate erosion in a limited area; 3 =more extensive
erosion; 4 = general destruction. The degree of synovial
pathology (i.e., synovitis) was scored using a scoring sys-
tem that measured the thickness of the synovial cell layer
on a scale of 0–3 (0 = 1–2 cells, 1 = 2–4 cells, 2 = 4–9 cells,
and 3 = 10 or more cells) and cellular density in the syn-
ovial stroma on a scale of 0–3 (0 = normal cellularity, 1 =
slightly increased cellularity, 2 =moderately increased cel-
lularity, and 3 = greatly increased cellularity) [23].
Cytokine quantification
Interleukin (IL)-17 and interferon (IFN)-γ cytokines were
measured by enzyme-linked immunosorbent assay
(ELISA) from hind paw homogenate of an individual
mouse using antibodies according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA). The
results were expressed as pg of cytokine/mg of tissue.
Myeloperoxidase assay
Myeloperoxidase (MPO) activity in tissue homogenates
was used as an index of neutrophil infiltration into paws
from CIA mice as previously described [24].
Measurement of liver enzymes
Serum concentrations of aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) were measured
using commercial kits according to the manufacturer’s in-
structions (ID Labs Biotechnology Inc., London, Canada).
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Antigen-induced arthritis (AIA)
Mice were immunized with methylated bovine serum albu-
min (mBSA; Sigma-Aldrich, St. Louis, MO, USA) as de-
scribed previously [25]. Briefly, mice were immunized with
subcutaneous injection of an emulsion with mBSA (500 μg;
Sigma-Aldrich, St. Louis, MO, USA) and CFA (2 mg/ml of
inactivated Mycobacterium tuberculosis; Sigma-Aldrich, St.
Louis, MO, USA). Booster injections of mBSA in IFA were
given at 7 and 14 days after the first immunization. On day
21 after the first immunization, arthritis was induced by an
intra-articular injection of mBSA (30 μg). During the AIA
protocol, LAP (10 mg/kg) or saline (vehicle) was given or-
ally every day from 12 to 21 days after first immunization.
Determination of joint leucocyte infiltration
Leucocyte infiltration into the joints was assessed 6 h
after intra-articular challenge with mBSA as previously
described [26]. Briefly, articular infiltration of leukocytes
was determined by washing the femur-tibial joint three
times with 3.3 μl phosphate-buffered aline (PBS) + EDTA
(0.2 M) and subsequent cell counting was performed in
a Neubauer chamber. The results were expressed as the
numbers of leucocyte × 104 (mean ± SEM)/joint.
Anti-mBSA antibody titer measurement
The titers of serum anti-mBSA antibody were measured
by ELISA as previously described [26].
Recall experiments
Cell suspension (1 × 105 cells) of draining lymph nodes
(inguinal) and spleen from naive and mBSA-immunized
(treated or not with LAP) mice were stimulated in a 96-
well round-bottom plate with mBSA (100 μg/ml) for
96 h. Next, the supernatant was collected to measure
the levels of IL-17A, IFN-γ, and IL-4 by ELISA (R&D
Systems, Minneapolis, MN, USA).
Statistical analysis
Statistical analyses were performed using one-way non-
parametric analysis of variance (ANOVA) followed by
Bonferroni’s t test (for three or more groups) comparing
all pairs of columns, or two-tailed Student’s t test (for
two groups). P < 0.05 was considered statistically signifi-
cant. Statistical analysis was performed with GraphPad
Prism (GraphPad Software, San Diego, CA, USA).
Results
Synthesis, molecular modeling, and ability of LAP to
inhibit DHODH activity
LAP was synthetized using lawsone as the starting material
in a one-pot methodology involving initial Knoevenagel
condensation followed by formic acid catalyzed reduction
in 78% yield. To increase the solubility of LAP, this
naphthoquinone was treated with NaOH for 24 h to afford
the LAP sodium salt in 95% yield (Fig. 1a). The structure of
the salt was confirmed by 1H and 13C NMR and high-
resolution mass spectrometry. Analysis of the LAP sodium
salt stability on plasma and acid media (similar to the stom-
ached conditions) was carried out using ultra-performance
liquid-chromatography tandem mass spectrometry (UPLC-
MS/MS) and it confirmed the instantaneous conversion of
LAP sodium salt into a neutral molecule of LAP. The indi-
vidual plasma profiles of LAP and LAP sodium salt after
intravenous administration were identical and were best
described by a two-compartmental open model, with a vol-
ume of distribution of 0.19 ± 0.03 l/kg, a total clearance of
0.04 ± 0.01 l/h/kg, and a half-life of 4.1 ± 1.1 h (Additional
file 1: Figure S1; Additional file 2: Table S1). Linear pharma-
cokinetics were observed in the dose range investigated
(2–25 mg/kg). Plasma profiles after oral administration of
LAP and LAP sodium salt (at two different doses) were best
described by the one-compartmental model, with bioavail-
abilities of 55–77% and 42%, respectively (Additional file 1:
Figure S1; Additional file 3: Table S2).
Subsequently, we performed a computational analysis for
the LAP molecule to propose a binding model in the active
site of human DHODH (hDHODH), using a flexible dock-
ing approach implemented in the GOLD software [18]. As
a control, we used the crystallographic binding mode of the
active metabolite A771726 inside the hDHODH active site
(PDB ID:1D3H). The binding model for LAP inside the
hDHODH active site, proposed by docking, indicates that
the hydrophobic pocket of hDHODH would be able to
allow an accommodation of the prenyl (in hydrophobic
contact with Phe98) and naphthoquinone moieties (in
hydrophobic contact with Val134 and Val143) of LAP
(Fig. 1b). Additional hydrogen bonds would be formed be-
tween the two carbonyl groups of such an inhibitor and
Arg136 and Tyr356 of hDHODH, residues well conserved
amongst the mammalian enzymes. The same polar contacts
are also observed between these two hDHODH residues
and the crystallographic inhibitor A771726 (PDB id: 1D3H)
(Additional file 4: Figure S2) [5]. Next, to address whether
LAP inhibits the DHODH activity, we carried out a cell-
free DHODH activity assay by measuring the reduction of
DCIP [12]. The hDHODH activity was significantly inhib-
ited by LAP sodium salt with an IC50 value of 0.13 μM
(Fig. 1c), indicating that LAP is a potent inhibitor of the
hDHODH activity.
LAP inhibits lymphocyte proliferation through inhibition
of pyrimidine biosynthesis
We next assessed the antiproliferative effect of LAP. To this
end, freshly isolated mouse CD4 T cells were labelled with
Dye Efluor 670 and stimulated with anti-CD3/CD28 in the
presence of LAP or LEF (10, 30, and 100 μM) for 4 days.
As shown in Fig. 2a, LAP or LEF inhibited the proliferation
of murine CD4 T cells in a dose-dependent manner. We
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also investigated the effect of LAP in human CD4 T cells
isolated from the peripheral blood of healthy donors. Simi-
lar to that observed with murine cells, we also found a
dose-dependent inhibition of human T-cell proliferation in
the presence of LAP or LEF (Fig. 2b). However, we found
that LAP exhibited a greater ability to suppress the prolifer-
ation of human and murine CD4 T cells than was observed
with LEF at the same equivalent concentrations (Fig. 2a
and b). Additionally, we performed annexin-V/propidium
iodide (PI) staining of human CD4 T cells treated with LAP
or LEF to assess apoptotic cell death. While LEF showed no
toxic effects at all concentrations, flow cytometric analysis
revealed that only the highest concentration of LAP
(100 μM) was toxic (Additional file 5: Table S3). Thus, the
reduction of T-cell proliferation by LAP below 100 μM was
primarily due to inhibition of the proliferative response ra-
ther than a reduction of cellular viability by toxicity.
The antiproliferative effect of LEF is completely reversed
by supplementation of uridine, supporting that DHODH is
the target for LEF [4]. We then investigated whether the
antiproliferative effect of LAP is also due to targeting
DHODH. To this end, human CD4 T cells were pretreated
with LAP in the presence of different concentrations of
uridine. As shown in Fig. 2c, uridine was able to reverse the
antiproliferative effect of LAP in a dose-dependent manner.
Of note, uridine alone had a minimal effect on the prolifer-
ative response of anti-CD3-stimulated T cells.
LAP reduces the severity of experimental arthritis
We next examined the therapeutic potential of LAP in
two experimental models of arthritis. The first model was
collagen-induced arthritis (CIA), a well-established T cell-
dependent preclinical model for RA [27]. Treatment with
LAP was started just after booster injection with collagen
on day 21 after the first immunization. Mice were orally
treated with LAP (3 mg/kg and 10 mg/kg) once a day for
4 weeks. LAP was well tolerated without apparent side ef-
fects based on observations of the general symptoms of
toxicity, including piloerection, diarrhea, weight loss, and
prostration. We also found that treatment with LAP did
not alter the serum levels of ALT or AST during the CIA
protocol (Additional file 6: Figure S3), indicating that it
Fig. 1 LAP is a potent inhibitor of DHODH activity. a Synthetic strategy for developing LAP sodium salt from lawsone. b The top-ranked GOLD solution for
LAP is shown inside the hDHODH active site, in hydrophobic and polar contacts with selected residues of the enzyme. Hydrogen bonds are here
represented by dashed magenta lines. c Inhibitory effect of LAP on human dihydroorotate dehydrogenase (hDHODH). Half maximal inhibitory concentration
(IC50) determination of LAP based on DCIP colorimetric assay
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was not hepatotoxic at the doses used. As a positive thera-
peutic control, mice were treated with LEF (3 mg/kg)
using the same treatment schedule. The doses of LEF and
LAP used in this therapeutic protocol were based on pre-
vious reports [28]. Clinical arthritis scores were recorded
from booster injection (day 0) and graded on a scale of
the magnitude of paw swelling, erythema, and ankylosis
(as described in the Methods section). We found that
LAP, at both doses used, markedly attenuated the severity
of arthritis in CIA mice, similar to those observed in mice
treated with LEF, as evidenced by a reduction of clinical
score and the number of affected paws (Fig. 3a).
Histopathological analysis of knee joint sections from
vehicle-treated mice stained with H&E and Safranin-O re-
vealed inflammatory cell infiltration, pannus formation,
and cartilage loss when compared to naive mice (Fig. 3b
and c). Notably, LAP markedly reduced all histopatho-
logical features of arthritis severity when compared to the
vehicle-treated group. No significant differences in histo-
pathological features were observed between mice treated
with LAP and LEF (Fig. 3b and c). Additionally, we mea-
sured the levels of inflammatory cytokines and MPO activ-
ity, which indirectly reflects neutrophil infiltration, in the
hind paws from CIA mice treated or not with LAP or LEF.
Fig. 2 LAP modulates lymphocyte proliferation in a dependent pyrimidine biosynthesis manner. Murine CD4 T cells were purified from lymph nodes
of naive C57BL/6 male mice and labeled with 1 μM Dye Efluor® 670 for 15 min at 37 °C and stimulated for 4 days in the presence of anti-CD3 (3 μg/
ml) and anti-CD28 (1.5 μg/ml). Cells were concomitantly incubated in the presence of lapachol (Lap) or leflunomide (Lef) (10, 30 and 100 μM). a The
percentage of suppression was assessed by the proliferation of murine CD4 T cells assessing dye dilution in flow cytometry analysis. Human CD4 T cells
were purified from blood of healthy volunteers and labeled with 1 μM Dye Efluor® 670 for 15 min at 37 °C and stimulated for 4 days in the presence
of anti-CD3 (3 μg/ml) and anti-CD28 (1.5 μg/ml). Cells were concomitantly incubated in the presence of LAP or LEF (10, 30 and 100 μM). b The
percentage of suppression was assessed by the proliferation of human CD4 T cells assessing dye dilution in flow cytometry analysis. Human CD4 T cells
were purified from blood of healthy volunteers and labeled with 1 μM Dye Efluor® 670 for 15 min at 37 °C and stimulated for 4 days in the presence
of anti-CD3 (3 μg/ml) and anti-CD28 (1.5 μg/ml). Cells were concomitantly incubated or not with LAP (10, 30, and 100 μM) and/or uridine (30, 100, and
300 μM). c The percentage of suppression was assessed by the proliferation of human CD4 T cells assessing dye dilution in flow cytometry analysis.
The results were expressed using the following formula: [proliferation of CD4 T cells only – (proliferation of CD4 T cells with LEF or LAP)/proliferation of
CD4 T cells only] × 100. Data are shown as mean ± SEM, n = 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 3 (See legend on next page.)
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We did not found any significant differences in IFN-γ levels
among all groups (Fig. 3d). However, CIA mice treated with
LAP with the dose of 10 mg/kg showed a significant reduc-
tion in IL-17A levels (Fig. 3e). Moreover, we found that
mice treated with LAP or LEF showed reduced MPO activ-
ity compared to vehicle-treated CIA mice (Fig. 3e).
Finally, we investigated the immunomodulatory effects of
LAP in a second model of experimental arthritis. To this
end, we employed the antigen-induced arthritis (AIA)
model in C57BL/6 mice, which also requires a T-cell re-
sponse for the generation of the acute articular inflamma-
tion [29]. Briefly, mice were treated orally with LAP
(10 mg/kg) once a day over 9 days, beginning 12 days after
the first immunization with the antigen mBSA. On day 21
after the first immunization, arthritis was induced by intra-
articular injection of mBSA into the knees of immunized
mice. We did not find differences in the serum levels of
anti-mBSA total IgG between mBSA-immunized mice
treated or not (vehicle) with LAP (Additional file 7: Figure
S4). However, mice treated with LAP exhibited a remark-
able reduction in leucocyte infiltration into the knee joint
6 h after mBSA challenge when compared to vehicle-
treated mice (Fig. 4a). We then evaluated the recall re-
sponses by cells from mBSA-immunized mice treated or
not with LAP. The mBSA-specific production of IL-17 and
IFN-γ by draining lymph node cells and splenocytes was
significantly reduced in mice treated with LAP (Fig. 4b and
c). IL-4 was not detected in the supernatant of stimulated
cells (data not shown). Collectively, these findings show the
marked immunomodulatory effects of LAP in two models
of experimental arthritis.
Discussion
In the present study, we conducted a series of in silico, in
vitro and in vivo studies describing the biological activity
and pharmacokinetic properties of LAP, which is a novel
immunosuppressive drug that attenuates experimental
autoimmune arthritis through inhibition of DHODH activ-
ity. Firstly, we synthetized LAP and performed chemical
modifications to improve its solubility in water. In accord-
ance with a previous report [9], we found that LAP can in-
hibit the enzymatic activity of hDHODH in vitro.
Moreover, we also provided a convincing model for the
interaction of LAP with hDHODH by computational
docking studies, indicating similar interactions observed
with A771726, the active metabolite of LEF. Specifically, the
narrow and relatively good hydrophobic pocket of
hDHODH allows a suitable accommodation of hydrophobic
prenyl and aromatic moieties from LAP. In this case, the
analyses predicted a consensual binding mode amongst all
the poses calculated for LAP, which additionally interacts by
hydrogen bonds with Arg136 and Tyr356 of hDHODH, res-
idues well conserved amongst the mammalian enzymes [5].
LAP is a naturally occurring naphthoquinone that has
been reported to exhibit antitumor, anti-inflammatory, and
antimicrobial activities, but the molecular mechanism
underlining these effects is poorly understood [9–15]. It
was previously reported that some naphthoquinones deriv-
atives, including LAP, can inhibit DHODH activity [9], but
the biological relevance of this observation was not investi-
gated. DHODH is a mitochondrial enzyme that catalyzes
the rate-limiting step of the de novo pyrimidine synthesis
[5]. Using lymphocyte proliferation assays, we demon-
strated that LAP has a potent immunosuppressive activity
on human and murine lymphocytes. Supplementation with
uridine, which overcomes the inhibition of pyrimidine syn-
thesis, reversed the antiproliferative activity of LAP on lym-
phocytes in vitro, demonstrating that the molecular
mechanism underlying the antiproliferative effect is mainly
due to DHODH inhibition. Importantly, we found that
LAP exhibits a greater ability to suppress the proliferation
of T cells than observed with LEF in vitro. These results
suggest that LAP has immunosuppressive activity on lym-
phocytes through its direct ability to block DHODH activity
and, consequently, inhibit pyrimidine synthesis.
In the pathogenesis of RA, it is well accepted that the in-
flux and proliferation of T cells in the synovial space play a
critical role in the articular inflammation and joint destruc-
tion [1, 27, 30]. In fact, autoreactive activated T cells in the
joint stimulate plasma cells, mast cells, macrophages, and
synovial fibroblasts to produce inflammatory mediators,
which in turn stimulate matrix degradation [4]. Therefore,
compounds that inhibit T-cell proliferation have been in-
troduced into the therapeutic schedule of RA [2]. LEF is a
widely used antiproliferative and immunosuppressive drug
for treatment of RA that targets DHODH [4]. However,
around 30–40% of RA patients do not have an appropriate
response to LEF [7]. Thus, identification of new small
(See figure on previous page.)
Fig. 3 Immunomodulatory effects of LAP on collagen-induced arthritis (CIA). DBA1/J male mice were injected i.d. at the base of the tail with 200 μg
CII emulsified in CFA on day 0. Mice were boosted i.d. with CII (200 μg emulsified in IFA) on day 21. After arthritis induction, mice were treated orally
with lapachol (Lap) (3 mg/kg and 10 mg/kg) or leflunomide (Lef) (3 mg/kg) or saline daily. a Clinical score/mouse (left panel) and affected paws/mouse
(right panel) were addressed daily after arthritis induction. Data represent mean, n = 5 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001. b, c Histological
analysis of CIA mice treated with LAP (3 mg/kg and 10 mg/kg) or LEF (3 mg/kg). Representative images of knee joint sections stained with H&E (b) or
Safranin-O (c) and respective histopathological scores. Magnification for H&E: upper row 100×; lower row 400×; Safranin-O: upper row in 100×; lower row
in 250×. Data represent mean, n = 5 in the vehicle and naive groups, n = 4 in Lef, Lap3 and Lap10 groups. *P < 0.05, **P < 0.01. Production of interferon
gamma (IFN-γ) (d) and interleukin-17A (IL-17A) (e) tissue levels from paws of CIA mice at 4 weeks after the boost with CII. f Myeloperoxidase (MPO)
activity from paws of CIA mice at 4 weeks after the boost with CII. Data represent mean ± SEM, n = 5 mice per group. *P < 0.05, **P < 0.01
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molecule inhibitors targeting DHODH constitutes an at-
tractive therapeutic approach for RA. Taking into account
that LAP shows a great ability to inhibit DHODH in vitro,
we hypothesized that LAP could have a therapeutic poten-
tial in the context of arthritis by interfering with T-cell pro-
liferation. In accordance with its immunosuppressive
activity in vitro, we found that LAP effectively attenuated
arthritis development and progression in two well-
established T cell-dependent models of autoimmune arth-
ritis. Moreover, mice treated with LAP showed a reduction
in joint inflammation and articular damage at similar effect-
iveness as LEF.
Synovial tissue infiltrating inflammatory cells from RA
patients are more resistant to apoptotic events, contrib-
uting to their accumulation and, consequently, the per-
sistence of inflammation [31]. The exact mechanism that
drives the leucocyte resistance to apoptosis in RA re-
mains unclear, but it is believed that proinflammatory
cytokines released in the synovial fluid microenviron-
ment are responsible for this phenomenon [32]. Since
LAP is reducing the production of T cell-dependent pro-
inflammatory cytokines in vivo, it could be indirectly
interfering with the apoptosis of inflammatory cells.
Thus, LAP and its derivate comprise a potential option
for the development of novel lead candidates for treating
RA based on DHODH inhibition. Indeed, β-lapachone, a
closely related secondary metabolite of LAP, is a promis-
ing drug candidate currently in Phase II clinical trials for
the treatment of cancer based on its ability to inhibit
DHODH (ClinicalTrials.gov identifier: nCT01502800;
ClinicalTrials.gov identifier: nCT02514031). However,
further studies are needed to determine whether LAP
will be effective in inhibiting proliferation of T cells from
RA patients who show an inadequate response to LEF.
Conclusions
In summary, this study demonstrated that LAP is a
novel immunosuppressive drug that attenuates experi-
mental autoimmune arthritis through inhibition of
DHODH activity. Therefore, LAP could be considered
as a potential immunosuppressive lead candidate with
potential therapeutic implications for RA.
Additional files
Additional file 1: Figure S1. Mean concentration–time profiles of lapachol
after (A) 2 mg/kg i.v., (B) 10 mg/kg oral, and (C) 25 mg/kg oral administration
to rats. Data points are mean ± standard deviation. (PDF 146 kb)
Additional file 2: TableS1. LAP and LAP sodium salt pharmacokinetic
parameters determined by noncompartmental and compartmental
approaches after i.v. administration of 2 mg/kg in Wistar rats. (PDF 93 kb)
Additional file 3: Table S2. Pharmacokinetic parameters after oral
administration of lapachol (10 mg/kg and 25 mg/kg) and LAP sodium
salt (30 mg/kg) in Wistar rats. (PDF 79 kb)
Additional file 4: Figure S2. Superimposition of the crystallographic
hDHODH inhibitor A771726 (PDB id:1D3H, carbon atoms in cyan) and the
top-ranked docking solution (carbon atoms in yellow), inside the active
site. (PDF 458 kb)
Additional file 5: Table S3. Evaluation of the toxicity of lapachol in
proliferating CD4 T cells. (PDF 224 kb)
Additional file 6: Figure S3. Serum levels of GPT and AST in LAP-treated
mice during CIA protocol. (PDF 518 kb)
Additional file 7: Figure S4. Serum titers of anti-mBSA antibodies in
LAP-treated mice on antigen-induced arthritis (AIA). (PDF 767 kb)
Fig. 4 Immunomodulatory effects of LAP on antigen-induced arthritis (AIA). Methylated bovine serum albumin (mBSA)-immunized C57BL/6 mice
were treated orally with lapachol (LAP) (10 mg/kg) once a day over 9 days, beginning 12 days after the first immunization. On day 21 after the first
immunization, mice were challenged with an intra-articular injection of 30 μg mBSA. a Leucocyte infiltration into the knee joint analyzed 6 h after
mBSA challenge. b, c A pool of cell suspension of draining lymph nodes (inguinal) and spleen from naive or mBSA-immunized mice treated or
not with LAP stimulated with mBSA (100 μg/ml) for 96 h. Production of interleuking-17A (IL-17A) (b) and interferon gamma (IFN-γ) (c) by splenic
and draining lymph node cells in response to mBSA stimulation measured by ELISA in the culture supernatant. Data represent mean ± SEM, naive
(n = 8), vehicle (n = 12), and LAP (n = 14). ***P < 0.001. N.D. not determined
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